201 related articles for article (PubMed ID: 27103427)
1. LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer.
Vargas A; Machado RD; Filho DI; Paiva CE; Dos Reis RB; Tobias-Machado M; Faria EF
World J Urol; 2016 Dec; 34(12):1621-1628. PubMed ID: 27103427
[TBL] [Abstract][Full Text] [Related]
2. Subcapsular orchiectomy versus total orchiectomy and LHRH analogue in the treatment of hormone-sensitive metastatic prostate cancer: a different perspective in evaluation of the psychosocial effects.
Selvi I; Basar H
Support Care Cancer; 2020 Sep; 28(9):4313-4326. PubMed ID: 31912363
[TBL] [Abstract][Full Text] [Related]
3. Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review.
Zhang X; Zhang G; Wang J; Wang Y
Front Endocrinol (Lausanne); 2023; 14():1131715. PubMed ID: 36814583
[TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
[TBL] [Abstract][Full Text] [Related]
5. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
[TBL] [Abstract][Full Text] [Related]
6. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
7. Metabolic consequences of gonadotropin-releasing hormone agonists vs orchiectomy: a randomized clinical study.
Østergren PB; Kistorp C; Fode M; Bennedbaek FN; Faber J; Sønksen J
BJU Int; 2019 Apr; 123(4):602-611. PubMed ID: 30388320
[TBL] [Abstract][Full Text] [Related]
8. [Androgen deprivation therapy and morbid obesity: do they share cardiovascular risk through metabolic syndrome?].
Cleffi S; Neto AS; Reis LO; Maia P; Fonseca F; Wroclawski ML; Neves M; Pompeo AC; Del Giglio A; Faria EF; Tobias-Machado M
Actas Urol Esp; 2011 May; 35(5):259-65. PubMed ID: 21459486
[TBL] [Abstract][Full Text] [Related]
9. [LHRH analogues for the treatment of prostate cancer: an evidence level-based analysis].
Pfitzenmaier J; Altwein JE
Aktuelle Urol; 2009 Mar; 40(2):100-8. PubMed ID: 19253209
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy.
Sun M; Choueiri TK; Hamnvik OP; Preston MA; De Velasco G; Jiang W; Loeb S; Nguyen PL; Trinh QD
JAMA Oncol; 2016 Apr; 2(4):500-7. PubMed ID: 26720632
[TBL] [Abstract][Full Text] [Related]
11. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer.
Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M
Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616
[TBL] [Abstract][Full Text] [Related]
12. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients.
Wu CT; Yang YH; Chen PC; Chen MF; Chen WC
Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353
[TBL] [Abstract][Full Text] [Related]
13. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism.
Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L
Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040
[TBL] [Abstract][Full Text] [Related]
14. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
15. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
16. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.
Greenspan SL; Coates P; Sereika SM; Nelson JB; Trump DL; Resnick NM
J Clin Endocrinol Metab; 2005 Dec; 90(12):6410-7. PubMed ID: 16189261
[TBL] [Abstract][Full Text] [Related]
17. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study.
Potosky AL; Knopf K; Clegg LX; Albertsen PC; Stanford JL; Hamilton AS; Gilliland FD; Eley JW; Stephenson RA; Hoffman RM
J Clin Oncol; 2001 Sep; 19(17):3750-7. PubMed ID: 11533098
[TBL] [Abstract][Full Text] [Related]
18. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
19. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer.
Young JWS; Sutradhar R; Rangrej J; Marras C; Fleshner N; Alibhai SMH
World J Urol; 2017 Sep; 35(9):1417-1423. PubMed ID: 28204918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
